Nektar Therapeutics (NASDAQ:NKTR) stock surged 140% after the company announced its experimental drug rezpegaldesleukin met primary and key secondary endpoints in a Phase 2b study for moderate-to-severe atopic dermatitis.
June 24, 2025 - 14:58
By Pharos Investment Advisors Comments are Off
Nektar Therapeutics (NASDAQ:NKTR) stock surged 140% after the company announced its experimental drug rezpegaldesleukin met primary and key secondary endpoints in a Phase 2b study for moderate-to-severe atopic dermatitis.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved